Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-04
2009-08-18
Berch, Mark L (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S256000, C514S293000, C544S333000, C544S281000, C544S126000, C544S405000, C544S238000, C544S350000, C544S346000, C544S127000, C544S279000, C546S122000, C560S027000
Reexamination Certificate
active
07576209
ABSTRACT:
The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
REFERENCES:
patent: 7034026 (2006-04-01), Barnett et al.
patent: 2003/0199511 (2003-10-01), Li et al.
patent: 2005/0130977 (2005-06-01), Lindsley et al.
patent: 2005/0159422 (2005-07-01), Lindsley et al.
patent: 2005/0182256 (2005-08-01), Duggan et al.
patent: 2005/0222155 (2005-10-01), Bilodeau et al.
patent: 2005/0288294 (2005-12-01), Duggan et al.
patent: 2006/0270673 (2006-11-01), Duggan et al.
patent: 2007/0043001 (2007-02-01), Bilodeau et al.
patent: 2007/0082906 (2007-04-01), Bilodeau et al.
patent: 2007/0254901 (2007-11-01), Bilodeau et al.
patent: 2008/0009507 (2008-01-01), Cosford et al.
patent: 2008/0015212 (2008-01-01), Barnett et al.
patent: 2008/0280889 (2008-11-01), Bilodeau et al.
patent: 1 679 308 (2006-07-01), None
patent: WO 2004/096130 (2004-11-01), None
patent: WO 2005/007099 (2005-01-01), None
patent: WO 2005/100356 (2005-10-01), None
patent: WO 2006/036395 (2006-04-01), None
patent: WO 2006/065601 (2006-06-01), None
patent: WO 2006/110638 (2006-10-01), None
patent: WO 2006/135627 (2006-12-01), None
Basso, et al., Oncogene (2002) 21, 1159-1166.
Frogne, et al., Endocrine-Related Cancer (2005) 12, 599-614.
Koul, et al., Mol. Cancer Ther. 2006;5:637-644.
Beresford, et al., J. Interferon & Cytokine Res. 21:313-322 (2001).
Altomare, et al., Oncogene (2004) 23, 5853-5857.
Kelly, III Michael J.
Layton Mark E.
Sanderson Philip E.
Berch Mark L
Jaisle Cecilia M
Leff Matthew A.
Merck & Co. , Inc.
Muthard David A.
LandOfFree
Inhibitors of Akt activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of Akt activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of Akt activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4133154